Home » Newsletters » BioWorld Science

BioWorld Science

July 15, 2013

View Archived Issues

Elan profiles PLK-2 inhibitor ELN-582646 for the treatment of Parkinson's disease

Scientists discover novel small-molecule inhibitor of drug-resistant tuberculosis

Uncovering an amygdala-based mechanism and a potential drug target of PTSD

Auspex commences First-HD phase III trial of SD-809 in Huntington's disease

Omni Bio to provide funding for clinical trial of alpha-1-antitrypsin in GVHD

Hisamitsu Pharmaceutical begins phase II study of HP-3060

Vernalis begins phase Ib/II study of V-81444

Daiichi Sankyo reports results from phase III study of antiplatelet agent in Japan

Nymox reports data from pivotal trial of NX-1207

Namisol shows efficacy in treatment of spasticity and pain in MS

RXi Pharmaceuticals reports findings from second phase I study of RXI-109

Lilly reports promising result for LY-2409021 in patients with type 1 and 2 diabetes

Allergan patents novel prostanoid receptor antagonists

Millennium Pharmaceuticals divulges PI3K type 3 inhibitors

Tissue transglutaminase inhibitors emerge from Sanofi R&D

Alios BioPharma patent describes agents for RSV and influenza

CSIR researchers develop agents for tuberculosis

COPD withdrawn from Japanese NDA for fluticasone furoate/vilanterol

Diazepam nasal spray shows safety and bioavailability comparable to marketed rectal gel formulation

Ipsen and Harvard to collaborate on novel engineered botulinum toxins

FDA approves Gilotrif along with companion diagnostic for first-line treatment of metastatic NSCLC

FDA and EMA issue decisions regarding C-Path's trial simulation tool for Alzheimer's disease

Promising first data for AbbVie compound in mild to moderate Alzheimer's disease

PI3Kbeta inhibitors revealed in GlaxoSmithKline patent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...